Clinical and morphological effects of hyperbaric oxygen therapy in patients with interstitial cystitis associated with fibromyalgia.
Fibromyalgia
Hyperbaric medicine
Interstitial cystitis
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
05 Nov 2019
05 Nov 2019
Historique:
received:
05
04
2019
accepted:
28
10
2019
entrez:
7
11
2019
pubmed:
7
11
2019
medline:
19
3
2020
Statut:
epublish
Résumé
Interstitial Cystitis (IC) is a debilitating disorder of the bladder, with a multifactorial and poorly understood origin dealing with microcirculation repeated damages. Also Fibromyalgia (FM) is a persistent disorder whose etiology is not completely explained, and its theorized alteration of pain processing can compromise the quality of life. Both these conditions have a high incidence of conventional therapeutic failure, but recent literature suggests a significant beneficial response to Hyperbaric Oxygen Therapy (HBOT). With this study, this study we evaluated the effects of HBOT on quality of life, symptoms, urodynamic parameters, and cystoscopic examination of patients suffering from both IC and FM. We structured an observational clinical trial design with repeated measures (questionnaires, urodynamic test, and cystoscopy) conducted before and 6 months after a therapeutic protocol with hyperbaric oxygen for the treatment of patients suffering from both IC and FM. Patients were exposed to breathing 100% oxygen at 2 atm absolute (ATA) in a multiplace pressure chamber for 90 min using an oro-nasal mask. Patients undertook a cycle of 20 sessions for 5 days per week, and a second cycle of 20 sessions after 1 week of suspension. Twelve patients completed the protocol. Changes after HBOT were not significant, except for hydrodistension tolerance (mean pre-treatment: 409.2 ml; mean post-treatment: 489.2 ml; p < 0.05). A regression of petechiae and Hunner's ulcers was also noted 6 months after the completion of HBOT. Our study showed no improvement of symptoms, quality of life, and urodynamic parameters, except for hydrodistension, and a slight improvement in cystoscopic pattern. However, to date, we could not demonstrate the significance of overall results to justify the use of HBOT alone in patients with IC and FM. This observation suggests that additional studies are needed to better understand if HBOT could treat this subset of patients. NCT03693001 ; October 2, 2018. Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Interstitial Cystitis (IC) is a debilitating disorder of the bladder, with a multifactorial and poorly understood origin dealing with microcirculation repeated damages. Also Fibromyalgia (FM) is a persistent disorder whose etiology is not completely explained, and its theorized alteration of pain processing can compromise the quality of life. Both these conditions have a high incidence of conventional therapeutic failure, but recent literature suggests a significant beneficial response to Hyperbaric Oxygen Therapy (HBOT). With this study, this study we evaluated the effects of HBOT on quality of life, symptoms, urodynamic parameters, and cystoscopic examination of patients suffering from both IC and FM.
METHODS
METHODS
We structured an observational clinical trial design with repeated measures (questionnaires, urodynamic test, and cystoscopy) conducted before and 6 months after a therapeutic protocol with hyperbaric oxygen for the treatment of patients suffering from both IC and FM. Patients were exposed to breathing 100% oxygen at 2 atm absolute (ATA) in a multiplace pressure chamber for 90 min using an oro-nasal mask. Patients undertook a cycle of 20 sessions for 5 days per week, and a second cycle of 20 sessions after 1 week of suspension.
RESULTS
RESULTS
Twelve patients completed the protocol. Changes after HBOT were not significant, except for hydrodistension tolerance (mean pre-treatment: 409.2 ml; mean post-treatment: 489.2 ml; p < 0.05). A regression of petechiae and Hunner's ulcers was also noted 6 months after the completion of HBOT.
CONCLUSIONS
CONCLUSIONS
Our study showed no improvement of symptoms, quality of life, and urodynamic parameters, except for hydrodistension, and a slight improvement in cystoscopic pattern. However, to date, we could not demonstrate the significance of overall results to justify the use of HBOT alone in patients with IC and FM. This observation suggests that additional studies are needed to better understand if HBOT could treat this subset of patients.
TRIAL REGISTRATION
BACKGROUND
NCT03693001 ; October 2, 2018. Retrospectively registered.
Identifiants
pubmed: 31690286
doi: 10.1186/s12894-019-0545-6
pii: 10.1186/s12894-019-0545-6
pmc: PMC6833196
doi:
Banques de données
ClinicalTrials.gov
['NCT03693001']
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Références
Med Gas Res. 2018 Apr 18;8(1):29-33
pubmed: 29770194
Mayo Clin Proc. 2011 May;86(5):457-64
pubmed: 21531887
Eur Urol. 2004 May;45(5):662-9
pubmed: 15082211
Urology. 2001 Jun;57(6 Suppl 1):62-6
pubmed: 11378052
Urology. 2007 Oct;70(4):646-9
pubmed: 17707887
Pain Pract. 2016 Jun;16(5):620-8
pubmed: 25988526
PLoS One. 2015 May 26;10(5):e0127012
pubmed: 26010952
J Int Med Res. 2004 May-Jun;32(3):263-7
pubmed: 15174219
BMC Urol. 2011 May 24;11:11
pubmed: 21609485
Urology. 1997 May;49(5A Suppl):58-63
pubmed: 9146003
Neurourol Urodyn. 2019 Jan;38(1):97-106
pubmed: 30411813
Urology. 2011 Oct;78(4):971.e11-5
pubmed: 21813166
J Urol. 2004 Sep;172(3):945-8
pubmed: 15311005
Undersea Hyperb Med. 2014 May-Jun;41(3):247-52
pubmed: 24984320
Int J Urol. 2003 Oct;10 Suppl:S24-6
pubmed: 14641410
J Appl Physiol (1985). 2009 Mar;106(3):988-95
pubmed: 18845776
Arthritis Care Res (Hoboken). 2010 May;62(5):600-10
pubmed: 20461783
Urology. 2018 Jun;116:23-29
pubmed: 29604315
Eur Urol. 2004 Jul;46(1):108-13
pubmed: 15183555
Aktuelle Urol. 2010 Nov;41(6):361-8
pubmed: 21082515
Ther Adv Urol. 2017 Sep 29;9(12):263-270
pubmed: 29383031
PLoS One. 2015 Nov 20;10(11):e0143316
pubmed: 26587589
Eur Urol. 2008 Jan;53(1):60-7
pubmed: 17900797
Pain Manag Nurs. 2015 Dec;16(6):834-40
pubmed: 26259883
J Urol. 2010 Oct;184(4):1358-63
pubmed: 20719340
Ann Med. 2011 Nov;43(7):495-502
pubmed: 21770697
Aktuelle Urol. 2008 Jul;39(4):289-97
pubmed: 18663671
Urologiia. 2011 May-Jun;(3):3-5
pubmed: 21874665
J Urol. 2005 Jan;173(1):98-102; discussion 102
pubmed: 15592041
Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):70-6
pubmed: 17201738
Urology. 2002 Oct;60(4):573-8
pubmed: 12385909